Vnitr Lek 2021, 67(1):48-50 | DOI: 10.36290/vnl.2021.007

Current view on hepatitis B diagnosis and therapy

Petr Husa
Klinika infekčních chorob Lékařské fakulty MU a FN Brno, pracoviště Bohunice

Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors predominantly vaccination policy and migration. Chronic hepatitis B is a dynamic process reflecting the interaction between HBV replication and the host immune response and not all patients with chronic HBV infection have chronic hepatitis B. Stopping of nucleotide or nucleoside analogues (NA) therapy is a serious resolution due the danger of reactivation of viral replication associated with increasing HBV DNA level, ALT activity and inflammatory activity in the liver histology. The safest stopping rule for NA therapy is HBsAg loss what is the sign of immune control of HBV infection.

Keywords: chronic hepatitis B, tenofovir, entecavir, stopping therapy.

Published: March 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P. Current view on hepatitis B diagnosis and therapy. Vnitr Lek. 2021;67(1):48-50. doi: 10.36290/vnl.2021.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017, http://dx.doi.org/10.1016/j.hep.2017. 03. 021. Go to original source...
    2. AASLD guidelines for treatment of chronic hepatitis B. Datum vydání: listopad 2015. Dostupné na: https://www.aasld.org/sites/default/files/2019-06/Terrault_et_al-2016-Hepatology.pdf.
    3. Asian‑Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98. Go to original source... Go to PubMed...
    4. Husa P, Šperl J, Urbánek P, Fraňková S, Plíšek S, Kümpel P, Rožnovský L. Doporučený postup diagnostiky a léčby infekce virem hepatitidy B. Gastroent Hepatol 2017; 71(5) : 419-437. Go to original source...
    5. Husa P, Šperl J, Urbánek P, Fraňková S, Plíšek S, Kümpel P, Rožnovský L. Doporučený postup diagnostiky a léčby infekce virem hepatitidy B. Datum vydání doporučení: září 2017. Klin mikrobiol inf lek 2017; 23(4): 148-164.
    6. Brown SR. Hepatitis now: defining optimal treatment duration in HBV. Clinical Care Options. Dostupné na: https://www.clinicaloptions.com/hepatitis/programs/hepatitisnow2019/optimal‑hbv‑treatment‑duration/slides-2

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.